98 related articles for article (PubMed ID: 24076582)
1. Biology and management of therapy-related acute promyelocytic leukemia.
Lo-Coco F; Hasan SK; Montesinos P; Sanz MA
Curr Opin Oncol; 2013 Nov; 25(6):695-700. PubMed ID: 24076582
[TBL] [Abstract][Full Text] [Related]
2. Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease.
Au WY; Ma SK; Chung LP; Chim CS; Kwong YL
Ann Hematol; 2002 Nov; 81(11):659-61. PubMed ID: 12454706
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
4. How to manage acute promyelocytic leukemia.
Mi JQ; Li JM; Shen ZX; Chen SJ; Chen Z
Leukemia; 2012 Aug; 26(8):1743-51. PubMed ID: 22422168
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Sahara N; Takeshita A; Satoh H; Terada H; Ohno R
Leukemia; 2002 Apr; 16(4):617-22. PubMed ID: 11960341
[TBL] [Abstract][Full Text] [Related]
6. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Zhang T; Westervelt P; Hess JL
Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
Tong H; Li K; Mei C; Wang H; Chen Z; Jin J
Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
[No Abstract] [Full Text] [Related]
8. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia: recent advances in diagnosis and management.
Lo-Coco F; Ammatuna E; Montesinos P; Sanz MA
Semin Oncol; 2008 Aug; 35(4):401-9. PubMed ID: 18692690
[TBL] [Abstract][Full Text] [Related]
11. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
12. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.
Elliott MA; Letendre L; Tefferi A; Hogan WJ; Hook C; Kaufmann SH; Pruthi RK; Pardanani A; Begna KH; Ashrani AA; Wolanskyj AP; Al-Kali A; Litzow MR
Eur J Haematol; 2012 Mar; 88(3):237-43. PubMed ID: 22023492
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
Mayorga J; Richardson-Hardin C; Dicke KA
Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
[TBL] [Abstract][Full Text] [Related]
17. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions.
Lengfelder E; Hofmann WK; Nowak D
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1035-43. PubMed ID: 24053202
[TBL] [Abstract][Full Text] [Related]
20. Treatment concepts of acute promyelocytic leukemia.
Lengfelder E; Saussele S; Weisser A; Büchner T; Hehlmann R
Crit Rev Oncol Hematol; 2005 Nov; 56(2):261-74. PubMed ID: 16236522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]